Abstract:Ovarian cancer is the number one cause of death from gynecologic malignancy. A defective p53 pathway is a hallmark of ovarian carcinoma. The p53 mutation correlates significantly with resistance to platinum-based chemotherapy, early relapse and shortened overall survival in ovarian cancer patients. PUMA (p53 upregulated modulator of apoptosis), a BH3-only Bcl-2 family protein, was recently identified as a transcriptional target of p53 and a potent apoptosis inducer in various cancer cells. In this study, we showed that the induction of PUMA by cisplatin was abolished in p53-deficient SKOV3 cells. Elevated expression of PUMA-induced apoptosis and sensitized A2780s and SKOV3 ovarian cancer cells to cisplatin, and the combination of PUMA and low-dose cisplatin, significantly suppressed xenograft tumor growth in vivo through enhanced induction of apoptosis compared with treatment with PUMA or cisplatin alone. The effects of PUMA were mediated by enhanced caspase activation and release of cytochrome c and Smac (second mitochondria-derived activator of caspase) into the cytosol. Furthermore, PUMA chemosensitized intrinsically resistant SKOV3 cells to cisplatin through downregulation of B-cell lymphoma-extra large (Bcl-x(L)) and myeloid cell leukemia sequence 1 (Mcl-1). PUMA-mediated Bcl-x(L) downregulation mainly happened at the transcription level, whereas PUMA-induced Mcl-1 down-regulation was associated with caspase-dependent cleavage and proteasome-mediated degradation. To our knowledge, these data suggest a new mechanism by which overexpression of PUMA enhances sensitivity of SKOV3 cells to cisplatin by lowering the threshold set simultaneously by Bcl-x(L) and Mcl-1. Taken together, our findings indicate that PUMA is an important modulator of therapeutic responses of ovarian cancer cells and is potentially useful as a chemosensitizer in ovarian cancer therapy.

Pro-apoptotic Function of PUMA in Human Tumor

PUMA: a New Target in Cytoprotective and Tumor Therapy

PUMA, a potent killer with or without p53

Promoting apoptotic effect of p53 up-regulated modulator of apoptosis

PUMA, a Novel Proapoptotic Gene, Is Induced by p53

The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases

PUMA expression in pancreatic cancer and its clinical significance

PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells

Advance in PUMA and Cardiomyocyte Apoptosis

The Expression of PUMA in Colon Carcinoma Cells and Its Effect in Cell Apoptosis

Effects of Exogenous PUMA on Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells

The Nuclear Function of P53 is Required for Puma-Mediated Apoptosis Induced by Dna Damage

Exogenous P53 Upregulated Modulator of Apoptosis (PUMA) Decreases Growth of Lung Cancer A549 Cells

PUMA expression is significantly reduced in human cutaneous melanomas

The P53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-x(L) and Mcl-1.

A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.

The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Expression of PUMA in Papillary Thyroid Carcinoma and Its Role in Inducing Apoptosis

Proliferative and survival effects of PUMA promote angiogenesis

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

The Function of PML in P53-Dependent Apoptosis